TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30554466

Group type: EXPERIMENTAL
Intervention: Bromocriptine (Gr B) for 12 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (Gr A) for 12 weeks
Number of subjects: 50
Study: 28732491

Group type: EXPERIMENTAL
Intervention: Job retention vocational rehabilitation (VR)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Written advice only (control)
Number of subjects: 55
Study: 25785683

Group type: EXPERIMENTAL
Intervention: Local dexamethasone and lidocaine infiltration (Group DL)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Local lidocaine infiltration (Group L)
Number of subjects: 160
Study: 24780643

Group type: EXPERIMENTAL
Intervention: Fructose (60 g)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fructose (30 g)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sucrose (60 g)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Glucose (60 g)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fructose (60 g) and (30 g)
Number of subjects: 12
Study: 23071214

Group type: EXPERIMENTAL
Intervention: Sleep extension (addition of 1 hour of sleep relative to baseline habitual sleep duration on weekdays)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sleep restriction (elimination of 1 hour of sleep relative to baseline habitual sleep duration on weekdays)
Number of subjects: 34
Study: 19226471

Group type: EXPERIMENTAL
Intervention: Tolterodine ER 4 mg once-daily for 12 weeks
Number of subjects: 987

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 987

Group type: EXPERIMENTAL
Intervention: Tolterodine ER
Number of subjects: 987
Study: 17327446

Group type: EXPERIMENTAL
Intervention: DHEA
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 15295223

Group type: EXPERIMENTAL
Intervention: PncCRM vaccine
Number of subjects: 1490

Group type: COMPARATOR
Intervention: Control (hepatitis B vaccine)
Number of subjects: 1490
Study: 11266237

Group type: EXPERIMENTAL
Intervention: Nebulizer therapy
Number of subjects: 37

Group type: COMPARATOR
Intervention: High-dose inhaler therapy
Number of subjects: 37
Study: 10440656

Group type: EXPERIMENTAL
Intervention: Medtronic Freestyle
Number of subjects: 995

Group type: COMPARATOR
Intervention: Toronto SPV
Number of subjects: 995
Study: 7929770

Group type: EXPERIMENTAL
Intervention: Rapid bacterial identification and antimicrobial susceptibility testing (same-day procedure)
Number of subjects: 573

Group type: COMPARATOR
Intervention: Traditional overnight techniques for bacterial identification and antimicrobial susceptibility testing
Number of subjects: 573
Study: 3075178

Group type: EXPERIMENTAL
Intervention: Calcitonin (daily 100 MRC of salmon calcitonin intramuscularly)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Cimetidine (daily 1000 mg orally)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (De‐Nol - four times a day in doses of 5 ml diluted with 15 ml of water)
Number of subjects: 110
Study: 27691376

Group type: EXPERIMENTAL
Intervention: MOMCare (choice of brief interpersonal psychotherapy, pharmacotherapy, or both)
Number of subjects: 160

Group type: COMPARATOR
Intervention: MSS-Plus (intensive maternity support services)
Number of subjects: 160
Study: 25293524

Group type: EXPERIMENTAL
Intervention: 0.625 mg droperidol
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 1.25 mg droperidol
Number of subjects: 75

Group type: COMPARATOR
Intervention: 8 mg ondansetron
Number of subjects: 75
Study: 23703789

Group type: EXPERIMENTAL
Intervention: Y90 without Sorafenib (Group A)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Y90 with Sorafenib (Group B)
Number of subjects: 15
Study: 21361982

Group type: EXPERIMENTAL
Intervention: TPB + regret first
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: TPB + regret mixed
Number of subjects: 576

Group type: COMPARATOR
Intervention: TPB only
Number of subjects: 576
Study: 19703317

Group type: EXPERIMENTAL
Intervention: Pedometer group
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study: 16440422

Group type: EXPERIMENTAL
Intervention: 30 mg lansoprazole o.d.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 30 mg lansoprazole b.i.d.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both treatment groups (30 mg lansoprazole o.d. and 30 mg lansoprazole b.i.d.)
Number of subjects: 36
Study: 15359680

Group type: EXPERIMENTAL
Intervention: EID interface with maximally adequate instrumentation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EID interface with minimally adequate instrumentation
Number of subjects: 0

Group type: COMPARATOR
Intervention: PID interface with minimally adequate instrumentation
Number of subjects: 0
Study: 11151743

Group type: EXPERIMENTAL
Intervention: Quercetin aglycone (8 mg, 20 mg, 50 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Rutin (8 mg, 20 mg, 50 mg)
Number of subjects: 16
Study: 9380609

Group type: EXPERIMENTAL
Intervention: 2.4 g of piracetam combined with cognitive therapy
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: 4.8 g of piracetam combined with cognitive therapy
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 8269741

Group type: EXPERIMENTAL
Intervention: Surgical resection (segmentectomy, bisegmentectomy, enucleation) with controlled hypotension and temporary occlusion of the hepatoduodenal ligament
Number of subjects: 721

Group type: EXPERIMENTAL
Intervention: Regular sonography and determination of alpha-fetoprotein for early detection of HCC
Number of subjects: 721
Study: 3903821

Group type: EXPERIMENTAL
Intervention: Lysine-8-vasopressin (LVP) for 10 days, up to 13.5 LVP units
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lysine-8-vasopressin (LVP)
Number of subjects: 12
Study: 31607119

Group type: EXPERIMENTAL
Intervention: STET model for estimating PM1 concentrations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: STET model
Number of subjects: 0
Study: 29742587

Group type: EXPERIMENTAL
Intervention: Probenecid (25 mg/kg) and N-acetylcysteine (140 mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 27108746

Group type: EXPERIMENTAL
Intervention: Resveratrol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 23721352

Group type: EXPERIMENTAL
Intervention: Single-session sex education lesson on chlamydia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual teaching on STIs
Number of subjects: 0
Study: 21431376

Group type: EXPERIMENTAL
Intervention: Mobile-bearing TKA
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Fixed-bearing TKA
Number of subjects: 31

Group type: COMPARATOR
Intervention: Natural knee joints
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both TKA designs
Number of subjects: 31
Study: 19549743

Group type: EXPERIMENTAL
Intervention: GHR antagonist (pegvisomant, 10 mg/d)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 17825688

Group type: COMPARATOR
Intervention: Epoetin delta 15 IU/kg IV tiw for 4 weeks
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Epoetin delta 40 IU/kg IV tiw for 4 weeks
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Epoetin delta 100 IU/kg IV tiw for 4 weeks
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Epoetin delta 75 IU/kg IV
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Epoetin delta 75 IU/kg SC
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Epoetin delta 50 IU/kg tiw for 4 weeks
Number of subjects: 121

Group type: COMPARATOR
Intervention: Epoetin alfa 50 IU/kg tiw for 4 weeks
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Epoetin delta 100 IU/kg tiw for 4 weeks
Number of subjects: 121

Group type: COMPARATOR
Intervention: Epoetin alfa 100 IU/kg tiw for 4 weeks
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Epoetin delta 150 IU/kg IV
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Epoetin delta 300 IU/kg IV
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Epoetin delta 150 IU/kg SC
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Epoetin delta 300 IU/kg SC
Number of subjects: 121
Study: 14984181

Group type: EXPERIMENTAL
Intervention: Ozonated autohemotherapy (50 microg/ml)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Oxygen autohemotherapy
Number of subjects: 10
Study: 11158813

Group type: EXPERIMENTAL
Intervention: I(125) brachytherapy
Number of subjects: 623
Study: 8141635

Group type: EXPERIMENTAL
Intervention: Hemodialysis educational and support program (HESP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 2971473

Group type: EXPERIMENTAL
Intervention: perindopril
Number of subjects: 16
Study: 29880069

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) 40,000 IU
Number of subjects: 84

Group type: COMPARATOR
Intervention: Saline (NaCl 0.9%)
Number of subjects: 84
Study: 28760246

Group type: EXPERIMENTAL
Intervention: FDC 0.4/5 mg
Number of subjects: 510

Group type: COMPARATOR
Intervention: Tadalafil 5 mg
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: FDC 0.2/5 mg
Number of subjects: 510
Study: 26018348

Group type: EXPERIMENTAL
Intervention: CNI-free de novo immunosuppressive treatment (mycofenolate mofetil, steroids, basiliximab) with delayed introduction of sirolimus
Number of subjects: 27
Study: 23549975

Group type: EXPERIMENTAL
Intervention: Tonsillectomy
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control (watchful waiting)
Number of subjects: 86
Study: 21471671

Group type: EXPERIMENTAL
Intervention: Azelnidipine 16 mg/day
Number of subjects: 199

Group type: COMPARATOR
Intervention: Amlodipine 5 mg/day
Number of subjects: 199
Study: 19031934

Group type: EXPERIMENTAL
Intervention: Severe (grade 3 or 4) hematological toxicity during chemotherapy
Number of subjects: 475

Group type: COMPARATOR
Intervention: No severe myelotoxicity during chemotherapy
Number of subjects: 475
Study: 16877071

Group type: EXPERIMENTAL
Intervention: Silicone Ahmed Glaucoma Valve
Number of subjects: 132

Group type: COMPARATOR
Intervention: Polypropylene Ahmed Glaucoma Valve
Number of subjects: 132
Study: 15189632

Group type: EXPERIMENTAL
Intervention: Sexism condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Personal deservingness condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Discounting rejection (blaming it on discrimination)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Discounting rejection
Number of subjects: 0
Study: 10634823

Group type: EXPERIMENTAL
Intervention: alpha-tocopherol supplementation (50 mg daily)
Number of subjects: 28519

Group type: EXPERIMENTAL
Intervention: beta-carotene supplementation (20 mg daily)
Number of subjects: 28519

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 28519
Study: 9436798

Group type: EXPERIMENTAL
Intervention: Severe cystic PVL
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Moderate PVL
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (preterm infants without PVL)
Number of subjects: 66
Study: 8430681

Group type: EXPERIMENTAL
Intervention: Verapamil (80 mg twice a day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 60
Study: 3315581

Group type: EXPERIMENTAL
Intervention: APSAC (30U in 4 to 5 minutes)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Streptokinase (1.5 X 10(6) U in 60 minutes)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: APSAC
Number of subjects: 86

Group type: COMPARATOR
Intervention: Streptokinase
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 86
Study: 29178491

Group type: EXPERIMENTAL
Intervention: Etrolizumab (0.3 to 10 mg/kg, administered intravenously or subcutaneously)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Etrolizumab
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: PK and PD profiles predicted by the model
Number of subjects: 38
Study: 27589795

Group type: EXPERIMENTAL
Intervention: High-Nitrate Diet (HND)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control Diet (CD)
Number of subjects: 7
Study: 26184257

Group type: EXPERIMENTAL
Intervention: HEPA filtration for 21 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham filtration for 21 days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: HEPA filtration
Number of subjects: 20
Study: 22809293

Group type: EXPERIMENTAL
Intervention: Portrayal of negative consequences of alcohol use
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Portrayal of positive consequences of alcohol use
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (no exposure to any program)
Number of subjects: 108
Study: 21346218

Group type: EXPERIMENTAL
Intervention: Hematoma expansion (HE) definitions
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Absolute growth cutoffs
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Absolute growth definition
Number of subjects: 531
Study: 19032127

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol maintenance and reliever therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fixed combination treatments (budesonide/formoterol and salmeterol/fluticasone with terbutaline as needed)
Number of subjects: 0
Study: 16606471

Group type: EXPERIMENTAL
Intervention: Minimally invasive 'step-up approach' starting with drainage followed by videoscopic assisted retroperitoneal debridement (VARD)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Maximal necrosectomy by laparotomy
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Both procedures followed by continuous postoperative lavage (CPL)
Number of subjects: 88
Study: 12932111

Group type: EXPERIMENTAL
Intervention: 3D brain map using the 3D-SSP program
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (20 age-matched cases)
Number of subjects: 25
Study: 10942742

Group type: EXPERIMENTAL
Intervention: ICD
Number of subjects: 288

Group type: COMPARATOR
Intervention: Amiodarone/Metoprolol
Number of subjects: 288
Study: 8737097

Group type: EXPERIMENTAL
Intervention: Low dose warfarin and aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study: 8466726

Group type: EXPERIMENTAL
Intervention: Isradipine 1.25 mg twice daily
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Isradipine 2.5 mg twice daily
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Isradipine plus spirapril 3 mg
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Isradipine plus pindolol 5 mg
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Self-recorded blood pressure in a subgroup of 45 patients
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Overall treatment with isradipine
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Side-effects related to treatment
Number of subjects: 595
Study: 3740382

Group type: EXPERIMENTAL
Intervention: nalbuphine
Number of subjects: 28

Group type: COMPARATOR
Intervention: pethidine
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: nalbuphine and pethidine
Number of subjects: 28
Study: 29749663

Group type: EXPERIMENTAL
Intervention: HIT
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: RT
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: CT
Number of subjects: 45

Group type: COMPARATOR
Intervention: CG
Number of subjects: 45
Study: 26340058

Group type: EXPERIMENTAL
Intervention: Printed reminders sent to GPs every 4 months regarding patients who had not performed scheduled faecal occult blood test (FOBT) screening.
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group (no reminders).
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Printed reminders sent to GPs.
Number of subjects: 144
Study: 25668166

Group type: EXPERIMENTAL
Intervention: Target temperature management at 33 °C
Number of subjects: 939

Group type: COMPARATOR
Intervention: Target temperature management at 36 °C
Number of subjects: 939
Study: 22742205

Group type: EXPERIMENTAL
Intervention: IV montelukast 7 mg
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: IV montelukast 14 mg
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: IV montelukast 7 mg and 14 mg
Number of subjects: 242

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study: 20299485

Group type: EXPERIMENTAL
Intervention: 100 mg aspirin once daily
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 800 mg NCX 4016 b.i.d.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination of NCX 4016 and aspirin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 18853112

Group type: EXPERIMENTAL
Intervention: Langchuang No.1 or 2 (Chinese recipes) in addition to Western medicine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Western medicine alone
Number of subjects: 60
Study: 16422913

Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg, flexible-dose regimen (5 mg or 20 mg possible after 4 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vardenafil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12757990

Group type: EXPERIMENTAL
Intervention: Impaired fasting glucose (IFG)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Normoglycemic
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Total population
Number of subjects: 600
Study: 10391603

Group type: EXPERIMENTAL
Intervention: Flexible Laryngeal Mask Airway (FLMA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard Laryngeal Mask Airway (LMA)
Number of subjects: 40
Study: 8887179

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy
Number of subjects: 0
Study: 1997509

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (3.2 mg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (0.8 mg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Oral prednisolone (40 mg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Oral prednisolone (10 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High dose prednisolone (40 mg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low dose prednisolone (10 mg/day)
Number of subjects: 40
Study: 6426828

Group type: EXPERIMENTAL
Intervention: Sodium valproate (DPA) 400 mg
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 31092654

Group type: COMPARATOR
Intervention: 5% aciclovir cream
Number of subjects: 952

Group type: EXPERIMENTAL
Intervention: Medical grade kanuka honey (90%)/glycerine (10%) cream
Number of subjects: 952
Study: 29408453

Group type: EXPERIMENTAL
Intervention: 1 mg RAPA daily
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 27077693

Group type: EXPERIMENTAL
Intervention: STAND (Supporting Teens' Autonomy Daily)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Treatment As Usual (TAU)
Number of subjects: 128
Study: 25384211

Group type: EXPERIMENTAL
Intervention: IPPB or LIAM
Number of subjects: 40
Study: 23046331

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (CEUS)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Computed tomographic angiography (CTA)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both CEUS and CTA
Number of subjects: 62
Study: 20133153

Group type: EXPERIMENTAL
Intervention: Low Socioeconomic Status (SES)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Four SES risk factors (low monthly income, less than a college education, unmarried, unemployed)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control for prenatal depressive symptoms
Number of subjects: 198
Study: 18358636

Group type: EXPERIMENTAL
Intervention: Flickering stimuli presented in the training phase and filled stimuli presented in the testing phase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Filled stimuli presented in both training and testing phases
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Filled stimuli presented in the training phase and flickering stimuli presented in the testing phase
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 0
Study: 16006884

Group type: EXPERIMENTAL
Intervention: 400 IU vitamin E
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 12205255

Group type: EXPERIMENTAL
Intervention: SIMV+VG 4.5 (V(T mech) set at 4.5 mL/kg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: SIMV+VG 3.0 (V(T mech) set at 3.0 mL/kg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: SIMV+VG 4.5 and SIMV+VG 3.0
Number of subjects: 17

Group type: COMPARATOR
Intervention: SIMV
Number of subjects: 17
Study: 10063823

Group type: EXPERIMENTAL
Intervention: Ballistic resistance training (8 weeks of squat jump training)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (squat and leg press exercises at a 6RM load)
Number of subjects: 16
Study: 7723681

Group type: EXPERIMENTAL
Intervention: Nibbling diet (17 meals daily)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control diet (3 meals daily)
Number of subjects: 7
Study: 2046063

Group type: EXPERIMENTAL
Intervention: Continuous TENS (80 Hz)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Burst TENS
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Modulation TENS
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Random TENS
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Continuous TENS
Number of subjects: 84
Study: 6352383

Group type: EXPERIMENTAL
Intervention: Levamisole (150 mg orally once weekly)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study: 30136597

Group type: EXPERIMENTAL
Intervention: Pre-hospital heart rate ⩾100 beats per minute
Number of subjects: 1560
Study: 28550255

Group type: EXPERIMENTAL
Intervention: Sembragiline 1 mg
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Sembragiline 5 mg
Number of subjects: 542

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 542
Study: 25745496

Group type: EXPERIMENTAL
Intervention: Camel milk
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cow milk
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 23383224

Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate potassium (A/CP)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 11
Study: 22089970

Group type: EXPERIMENTAL
Intervention: Letrozole (Femara®)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 2